Related references
Note: Only part of the references are listed.Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease 2019
Emma Nichols et al.
LANCET PUBLIC HEALTH (2022)
A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M1 receptor agonist HTL0018318 in patients with mild-to-moderate Alzheimer's disease
Pradeep. J. J. Nathan et al.
ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS (2022)
Aβ oligomers induce pathophysiological mGluR5 signaling in Alzheimer's disease model mice in a sex-selective manner
Khaled S. Abd-Elrahman et al.
SCIENCE SIGNALING (2020)
mGluR5 Contribution to Neuropathology in Alzheimer Mice Is Disease Stage-Dependent
Khaled S. Abd-Elrahman et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2020)
Modulation of mTOR and CREB pathways following mGluR5 blockade contribute to improved Huntington's pathology in zQ175 mice
Khaled S. Abd-Elrahman et al.
MOLECULAR BRAIN (2019)
The neuropathological diagnosis of Alzheimer's disease
Michael A. DeTure et al.
MOLECULAR NEURODEGENERATION (2019)
In-vivo genetic ablation of metabotropic glutamate receptor type 5 slows down disease progression in the SOD1G93A mouse model of amyotrophic lateral sclerosis
Tiziana Bonifacino et al.
NEUROBIOLOGY OF DISEASE (2019)
A positive allosteric modulator of mGluR5 promotes neuroprotective effects in mouse models of Alzheimer's disease
Paula Maria Quaglio Bellozi et al.
NEUROPHARMACOLOGY (2019)
ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?
Rita Mejzini et al.
FRONTIERS IN NEUROSCIENCE (2019)
Huntington's disease: a clinical review
P. McColgan et al.
EUROPEAN JOURNAL OF NEUROLOGY (2018)
The mGluR5 positive allosteric modulator VU0409551 improves synaptic plasticity and memory of a mouse model of Huntington's disease
Juliana G. Doria et al.
JOURNAL OF NEUROCHEMISTRY (2018)
G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs?
Krishna Sriram et al.
MOLECULAR PHARMACOLOGY (2018)
Autophagy is increased following either pharmacological or genetic silencing of mGluR5 signaling in Alzheimer's disease mouse models
Khaled S. Abd-Elrahman et al.
MOLECULAR BRAIN (2018)
Biased agonism and allosteric modulation of metabotropic glutamate receptor 5
Phuc N. H. Trinh et al.
CLINICAL SCIENCE (2018)
L-DOPA-Induced Motor Impairment and Overexpression of Corticostriatal Synaptic Components Are Improved by the mGluR5 Antagonist MPEP in 6-OHDA-Lesioned Rats
Yixian Huang et al.
ASN NEURO (2018)
Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder
Brittany A. Jaso et al.
CURRENT NEUROPHARMACOLOGY (2017)
A comprehensive map of molecular drug targets
Rita Santos et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
α-synuclein interacts with PrPC to induce cognitive impairment through mGluR5 and NMDAR2B
Diana G. Ferreira et al.
NATURE NEUROSCIENCE (2017)
D mGluR5 antagonism increases autophagy and prevents disease progression in the zQ175 mouse model of Huntington's disease
Khaled S. Abd-Elrahman et al.
SCIENCE SIGNALING (2017)
β-Arrestin2 Couples Metabotropic Glutamate Receptor 5 to Neuronal Protein Synthesis and Is a Potential Target to Treat Fragile X
Laura J. Stoppel et al.
CELL REPORTS (2017)
D mGluR5 antagonism increases autophagy and prevents disease progression in the zQ175 mouse model of Huntington's disease
Khaled S. Abd-Elrahman et al.
SCIENCE SIGNALING (2017)
Parkinson disease
Werner Poewe et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Reactome enhanced pathway visualization
Konstantinos Sidiropoulos et al.
BIOINFORMATICS (2017)
Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients
Rajeev Kumar et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2016)
Intravenous Dosing as an Alternate Approach to Safely Achieve Supratherapeutic Exposure for Assessments of Cardiac Repolarization: A Randomized Clinical Trial with Mavoglurant (AFQ056)
Mike Ufer et al.
CLINICAL THERAPEUTICS (2016)
Excitotoxicity in ALS: Overstimulation, or overreaction?
Anna E. King et al.
EXPERIMENTAL NEUROLOGY (2016)
A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease
Francois Tison et al.
MOVEMENT DISORDERS (2016)
Rapid signalling in distinct dopaminergic axons during locomotion and reward
M. W. Howe et al.
NATURE (2016)
Transduction of group I mGluR-mediated synaptic plasticity by β-arrestin2 signalling
Andrew G. Eng et al.
NATURE COMMUNICATIONS (2016)
Chronic Pharmacological mGluR5 Inhibition Prevents Cognitive Impairment and Reduces Pathogenesis in an Alzheimer Disease Mouse Model
Alison Hamilton et al.
CELL REPORTS (2016)
Presynaptic Release-Regulating mGlu1 Receptors in Central Nervous System
Anna Pittaluga
FRONTIERS IN PHARMACOLOGY (2016)
Targeting the Cholinergic System to Develop a Novel Therapy for Huntington's Disease
Gary X. D'Souza et al.
JOURNAL OF HUNTINGTONS DISEASE (2016)
Basimglurant for treatment of major depressive disorder: a novel negative allosteric modulator of metabotropic glutamate receptor 5
Kjell Fuxe et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
PET imaging studies show enhanced expression of mGluR5 and inflammatory response during progressive degeneration in ALS mouse model expressing SOD1-G93A gene
Anna-Liisa Brownell et al.
JOURNAL OF NEUROINFLAMMATION (2015)
The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease
J. G. Doria et al.
NEUROBIOLOGY OF DISEASE (2015)
Epidemiology of Amyotrophic Lateral Sclerosis and Effect of Riluzole on Disease Course
Hakan Cetin et al.
NEUROEPIDEMIOLOGY (2015)
Basal Ganglia Circuits as Targets for Neuromodulation in Parkinson Disease
Mahlon R. DeLong et al.
JAMA NEUROLOGY (2015)
Metabotropic glutamate receptor 5 as a potential therapeutic target in Huntington's disease
Fabiola M. Ribeiro et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2014)
Metabotropic glutamate receptor 5 knockout promotes motor and biochemical alterations in a mouse model of Huntingtons disease
Fabiola M. Ribeiro et al.
HUMAN MOLECULAR GENETICS (2014)
Astrocyte-Derived BDNF Supports Myelin Protein Synthesis after Cuprizone-Induced Demyelination
Clifton G. Fulmer et al.
JOURNAL OF NEUROSCIENCE (2014)
Intracellular mGluR5 Can Mediate Synaptic Plasticity in the Hippocampus
Carolyn A. Purgert et al.
JOURNAL OF NEUROSCIENCE (2014)
mGluR5: Exploration of Orthosteric and Allosteric Ligand Binding Pockets and Their Applications to Drug Discovery
Christina Molck et al.
NEUROCHEMICAL RESEARCH (2014)
Novel mGluR5 Positive Allosteric Modulator Improves Functional Recovery, Attenuates Neurodegeneration, and Alters Microglial Polarization after Experimental Traumatic Brain Injury
David J. Loane et al.
NEUROTHERAPEUTICS (2014)
Metabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer's disease
Alison Hamilton et al.
MOLECULAR BRAIN (2014)
Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington's disease
J. G. Doria et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Molecular Mechanisms of Amyloid Oligomers Toxicity
Rakez Kayed et al.
JOURNAL OF ALZHEIMERS DISEASE (2013)
AFQ056 in Parkinson Patients With Levodopa-Induced Dyskinesia: 13-Week, Randomized, Dose-Finding Study
Fabrizio Stocchi et al.
MOVEMENT DISORDERS (2013)
The role of autophagy in neurodegenerative disease
Ralph A. Nixon
NATURE MEDICINE (2013)
Metabotropic Glutamate Receptor 5 Is a Coreceptor for Alzheimer Aβ Oligomer Bound to Cellular Prion Protein
Ji Won Um et al.
NEURON (2013)
Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys
Nicolas Morin et al.
NEUROPHARMACOLOGY (2013)
MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: Biochemical correlates
Nicolas Morin et al.
NEUROPHARMACOLOGY (2013)
Current and future treatments for Alzheimer's disease
Konstantina G. Yiannopoulou et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2013)
Genomic Analysis of Reactive Astrogliosis
Jennifer L. Zamanian et al.
JOURNAL OF NEUROSCIENCE (2012)
Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson's disease rat model
Ming-Hong Hsieh et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2012)
Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators as Novel Tools for in Vivo Investigation
Thomas M. Keck et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
Modeling Parkinson's Disease in Primates: The MPTP Model
Gregory Porras et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys
Gunasingh J. Masilamoni et al.
BRAIN (2011)
Quantitative Analysis Reveals Multiple Mechanisms of Allosteric Modulation of the mGlu5 Receptor in Rat Astroglia
Sophie J. Bradley et al.
MOLECULAR PHARMACOLOGY (2011)
Disease-Related Changes in the Cerebrospinal Fluid Metabolome in Amyotrophic Lateral Sclerosis Detected by GC/TOFMS
Anna Wuolikainen et al.
PLOS ONE (2011)
MPTP Mouse Models of Parkinson's Disease: An Update
Gloria E. Meredith et al.
JOURNAL OF PARKINSONS DISEASE (2011)
CTEP: A Novel, Potent, Long-Acting, and Orally Bioavailable Metabotropic Glutamate Receptor 5 Inhibitor
Lothar Lindemann et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Glutamatergic fine tuning with ADX-10059: a novel therapeutic approach for migraine?
Juana C. A. Marin et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Metabotropic Glutamate Receptor-Mediated Cell Signaling Pathways Are Altered in a Mouse Model of Huntington's Disease
Fabiola M. Ribeiro et al.
JOURNAL OF NEUROSCIENCE (2010)
Quantitative Relationships between Huntingtin Levels, Polyglutamine Length, Inclusion Body Formation, and Neuronal Death Provide Novel Insight into Huntington's Disease Molecular Pathogenesis
Jason Miller et al.
JOURNAL OF NEUROSCIENCE (2010)
Reduction of L-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease
Tom H. Johnston et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys
Daniella Rylander et al.
NEUROBIOLOGY OF DISEASE (2010)
Deleterious Effects of Amyloid β Oligomers Acting as an Extracellular Scaffold for mGluR5
Marianne Renner et al.
NEURON (2010)
Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys
Nicolas Morin et al.
NEUROPHARMACOLOGY (2010)
Turning REST/NRSF Dysfunction in Huntington's Disease into a Pharmaceutical Target
Dorotea Rigamonti et al.
CURRENT PHARMACEUTICAL DESIGN (2009)
The structure and function of G-protein-coupled receptors
Daniel M. Rosenbaum et al.
NATURE (2009)
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Juha Lauren et al.
NATURE (2009)
Focal degeneration of astrocytes in amyotrophic lateral sclerosis
D. Rossi et al.
CELL DEATH AND DIFFERENTIATION (2008)
Glutamate elicits release of BDNF from basal forebrain astrocytes in a process dependent on metabotropic receptors and the PLC pathway
Ying Y. Jean et al.
NEURON GLIA BIOLOGY (2008)
Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment
Bhomraj Thanvi et al.
POSTGRADUATE MEDICAL JOURNAL (2007)
The 6-hydroxydopamine model of Parkinson's disease
Nicola Simola et al.
NEUROTOXICITY RESEARCH (2007)
Regulation of metabotropic glutamate receptor signaling, desensitization and endocytosis
Gurpreet K. Dhami et al.
PHARMACOLOGY & THERAPEUTICS (2006)
Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox
Christopher J. Langmead et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2006)
Fenobam:: A clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity
RHP Porter et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Inhibition of metabotropic glutamate receptor signaling by the huntingtin-binding protein optineurin
PH Anborgh et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats
K Ossowska et al.
NEUROPHARMACOLOGY (2005)
The role of metabotropic glutamate receptor 5 in learning and memory processes
A Simonyi et al.
DRUG NEWS & PERSPECTIVES (2005)
Differential expression of mGluR5 in human lumbosacral motoneurons
JMH Anneser et al.
NEUROREPORT (2004)
Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice
G Battaglia et al.
JOURNAL OF NEUROSCIENCE (2004)
The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease
J Schlefer et al.
BRAIN RESEARCH (2004)
Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides that potentiate receptor function in vivo
CW Lindsley et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP
A Schober
CELL AND TISSUE RESEARCH (2004)
A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain
JA O'Brien et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Allosteric modulators of G-protein-coupled receptors
LT May et al.
CURRENT OPINION IN PHARMACOLOGY (2003)
A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5
JA O'Brien et al.
MOLECULAR PHARMACOLOGY (2003)
Huntingtin and Huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1
TS Tang et al.
NEURON (2003)
Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP
JM Mathiesen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2003)
[3H]-methoxymethyl-MTEP and [3H]-methoxy-PEPy:: Potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor
NDP Cosford et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
Direct and Indirect Modulation of the N-Methyl D-Aspartate Receptor: Potential for the Development of Novel Antipsychotic Therapies
M. J. Marino et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2002)
Differential subcellular localization of mGluR1a and mGluR5 in the rat and monkey substantia nigra
GW Hubert et al.
JOURNAL OF NEUROSCIENCE (2001)
Immunohistochemical localization of group I and II metabotropic glutamate receptors in control and amyotrophic lateral sclerosis human spinal cord: Upregulation in reactive astrocytes
E Aronica et al.
NEUROSCIENCE (2001)
Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism
DM O'Leary et al.
BRITISH JOURNAL OF PHARMACOLOGY (2000)
Effects of the prototypical mGlu5 receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats
WPJM Spooren et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2000)
Elevated cortical extracellular fluid glutamate in transgenic mice expressing human mutant (G93A) Cu/Zn superoxide dismutase
GM Alexander et al.
JOURNAL OF NEUROCHEMISTRY (2000)
Share Paper
